Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium

H Kiaris, K Politi, LM Grimm, M Szabolcs… - The American journal of …, 2004 - Elsevier
H Kiaris, K Politi, LM Grimm, M Szabolcs, P Fisher, A Efstratiadis, S Artavanis-Tsakonas
The American journal of pathology, 2004Elsevier
Deregulation of Notch signaling, which normally affects a broad spectrum of cell fates, has
been implicated in various neoplastic conditions. Here we describe a transgenic mouse
model, which demonstrates that expression of a constitutively active form of the Notch1
receptor in the mammary epithelium induces the rapid development of pregnancy/lactation-
dependent neoplasms that consistently exhibit a characteristic histopathological pattern.
These signature tumors retain the ability to respond to apoptotic stimuli and regress on …
Deregulation of Notch signaling, which normally affects a broad spectrum of cell fates, has been implicated in various neoplastic conditions. Here we describe a transgenic mouse model, which demonstrates that expression of a constitutively active form of the Notch1 receptor in the mammary epithelium induces the rapid development of pregnancy/lactation-dependent neoplasms that consistently exhibit a characteristic histopathological pattern. These signature tumors retain the ability to respond to apoptotic stimuli and regress on initiation of mammary gland involution, but eventually appear to progress in subsequent pregnancies to nonregressing malignant adenocarcinomas. Additionally, we present evidence indicating that cyclin D1 is an in vivo target of Notch signals in the mammary glands and demonstrate that we can effectively inhibit Hras1-driven, cyclin D1-dependent mammary oncogenesis by transgenic expression of the Notch antagonist Deltex.
Elsevier